These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1553063)

  • 1. [Bioavailability of orally administered iron. Effects of alginate/antacid administration].
    Campo S; Breda E
    Minerva Med; 1992 Mar; 83(3):145-7. PubMed ID: 1553063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric pH and endoscopic appearance after Algicon administration.
    Lambert JR; Korman MG; Nicholson L
    Br J Clin Pract Suppl; 1989 Feb; 66():25-8; discussion 35-6. PubMed ID: 2511920
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative intragastric pH profile of Algicon versus Gaviscon.
    Stoddard CJ; Morgan GE
    Br J Clin Pract Suppl; 1989 Feb; 66():29-34; discussion 35-6. PubMed ID: 2556174
    [No Abstract]   [Full Text] [Related]  

  • 4. [Alginate-containing preparation gaviscon for patients with gastroesophaginal reflux complicated with chronic pancreatitis: pathogenetic substantiation of clinical use prospects].
    Uspenskiĭ IuP; Pakhomova IG; Bubiakina VN
    Eksp Klin Gastroenterol; 2008; (1):96-101. PubMed ID: 19145860
    [No Abstract]   [Full Text] [Related]  

  • 5. The mode of action alginic acid compound in the reduction of gastroesophageal reflux.
    Malmud LS; Charkes ND; Littlefield J; Reilley J; Stern H; Rosenberg R; Fisher RS
    J Nucl Med; 1979 Oct; 20(10):1023-8. PubMed ID: 231639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [pH gradient support and antacid action of gastroesophageal coating agents. In vitro pharmacologic study using a model of "the artificial stomach"].
    Vatier J; Vitre MT; Vallot T; Mignon M
    Gastroenterol Clin Biol; 1990; 14(5):414-22. PubMed ID: 2163935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of antacids on the absorption of simultaneously ingested iron.
    O'Neil-Cutting MA; Crosby WH
    JAMA; 1986 Mar; 255(11):1468-70. PubMed ID: 3005669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gaviscon in reflux symptoms. Results of a drug monitoring study].
    Hutt HJ; Tauber O; Flach D
    Fortschr Med; 1990 Oct; 108(31):598-600. PubMed ID: 2258131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oesophagitis and the role of antacid therapy.
    Rhodes J
    Scand J Gastroenterol Suppl; 1982; 75():74-6. PubMed ID: 6959253
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of gastro-esophageal reflux using a potable gaviscon suspension].
    Guerre J; Neuman M; Bouchet J
    Med Chir Dig; 1982; 11(4):289-95. PubMed ID: 6287126
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of an aluminium-hydroxide containing antacid on the oral bioavailability of pirenzepine.
    Vergin H; Herrlinger C; Gugler R
    Arzneimittelforschung; 1989 Apr; 39(4):520-3. PubMed ID: 2751741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral iron therapy. Bioavailability and therapeutic effectiveness of ferrous iron in effervescent tablets in posthemorrhagic iron deficiency anemia].
    Kaltwasser JP; Schwarz-van de Sand W
    Dtsch Med Wochenschr; 1989 Aug; 114(31-32):1188-95. PubMed ID: 2666080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined cimetidine-alginate antacid therapy versus single agent treatment for reflux oesophagitis: results of prospective double-blind randomised clinical trial.
    Eriksen CA; Cheadle WG; Cranford CA; Cuschieri A
    Ann Chir Gynaecol; 1988; 77(4):133-7. PubMed ID: 2855391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative evaluation of the effectiveness of peroral treatment of patients with chronic posthemorrhagic anemia with iron-containing preparations].
    Bokarev IN; Andreeva VK; Astashenko NA; Gol'tiakova TV; Ershov VI
    Klin Med (Mosk); 1975 Nov; 53(11):110-3. PubMed ID: 1223501
    [No Abstract]   [Full Text] [Related]  

  • 15. Algicon in the management of gastro-oesophageal reflux.
    Lambert JR; Korman MG; Nicholson L
    Br J Clin Pract Suppl; 1989 Feb; 66():56-8; discussion 61-4. PubMed ID: 2556177
    [No Abstract]   [Full Text] [Related]  

  • 16. Antacid therapy--changes in mineral metabolism.
    Herzog P; Holtermüller KH
    Scand J Gastroenterol Suppl; 1982; 75():56-62. PubMed ID: 6293043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced oral itraconazole bioavailability by antacid suspension.
    Lohitnavy M; Lohitnavy O; Thangkeattiyanon O; Srichai W
    J Clin Pharm Ther; 2005 Jun; 30(3):201-6. PubMed ID: 15896236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Grounds and perspectives of using geviskon--novel in Russia alginate-containing drug--in treatment of acid-dependent diseases of the digestive system].
    Tkachenko EI; Uspenskiĭ IuP
    Eksp Klin Gastroenterol; 2007; (4):41-6. PubMed ID: 18409489
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic procedures in gastroesophageal reflux disease].
    Tytgat GN
    Z Gastroenterol; 1986 Sep; 24 Suppl 2():40-4. PubMed ID: 2877526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.